US Appeals Court Panel Questions FDA Due Diligence on Abortion Pill
BIOMARKER
1. A three-judge panel in Louisiana's 5th Circuit Court of Appeals probed the FDA's due diligence during oral arguments.
2. The U.S. Supreme Court granted the FDA's application for a stay in April, maintaining access to mifepristone.
3. Anti-abortion groups sued the FDA in November 2022.
4. The approval of mifepristone in 2000 was challenged by the groups.
5. The three-judge panel consisted of Jennifer Walker Elrod, James C. Ho, and Cory T. Wilson.
6. Judge James Ho questioned the FDA's infallibility during the hearing.
7. The attorney representing Danco Laboratories cited instances where patients took non-FDA-approved drugs or consumed mifepristone under certain medical conditions.
8. Major medical organizations, such as the American College of Obstetricians and Gynecologists, urged the court to uphold the legality of mifepristone.
9. The U.S. House Republicans introduced a funding bill to nullify the FDA's January changes.
10. The 5th Circuit Court of Appeals case could impact abortion access throughout the U.S.